)
Abbott Laboratories (ABT) investor relations material
Abbott Laboratories Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 net sales were $13.013B, up 14.5% reported and 7.0% comparable; net earnings fell 44.1% to $920M, while adjusted diluted EPS rose 9.2% to $1.42.
Plans call for a tax-free Nutrition separation by end-2027, subject to approvals; the rationale is to give each business distinct focus, investment priorities and operating flexibility.
Exact Sciences contributed to reported sales growth following its March acquisition; reported Diagnostics sales rose 46.7%, while comparable growth was 6.4%.
Financial highlights
Q3 GAAP diluted EPS was $0.53 versus $0.94; adjusted net earnings rose 8.7% to $2.477B. Q3 operating earnings fell 34.0% to $1.358B.
Adjusted gross margin was 57.2%, up 140 bps YoY; reported gross margin was 50.3%, down from 51.7%, reflecting acquisition amortization, higher costs and FX.
9M sales increased 11.9% to $36.770B; net earnings fell to $2.925B, while adjusted net earnings rose 5.9% to $6.789B.
9M operating cash flow was $5.540B versus $6.251B; net investing cash use was $21.382B, driven by acquisition-related outflows.
Outlook and guidance
FY26 comparable sales growth is projected at ~6.0%; adjusted diluted EPS guidance was reaffirmed at $5.50–$5.55. Q4 adjusted EPS guidance is $1.62–$1.67.
FY26 sales outlook implies Q4 growth just above 8%; Q4 FX is expected to reduce sales by ~1%. EP and diabetes growth and pricing dynamics are near-term factors.
For 2027, total sales growth is expected to accelerate; excluding Nutrition’s current profile, expected sales growth acceleration is 50–100 bps, gross-margin expansion >200 bps and operating-margin expansion ~100 bps.
- Operating earnings and margins improved as Nutritionals and Diagnostics led growth.ABT
Q4 2014 - Margins expanded in 2015, while disposition gains lifted reported net earnings.ABT
Q4 2015 - Sales grew, earnings absorbed major one-time charges, and St. Jude Medical reshaped the portfolio.ABT
Q4 2016 - Acquisitions expanded the portfolio, but integration costs and tax reform sharply reduced reported earnings.ABT
Q4 2017 - Organic growth across all four major businesses lifted FY18 sales to $30.6B.ABT
Q4 2018 - Organic sales grew 7.7% as adjusted EPS rose 12.5%.ABT
Q4 2019 - COVID-19 diagnostics propelled sales and earnings growth amid broad pandemic-driven business disruption.ABT
Q4 2020 - Broad-based growth lifted 2021 sales to $43.1B despite pandemic volatility and cost pressures.ABT
Q4 2021 - Medical-device and emerging-market growth helped offset formula recall and cooling COVID-test demand.ABT
Q4 2022
)
)
)
)
)
)
)
)